Literature DB >> 8383561

Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HT1B/D agonists and endopeptidase 24.11.

Z Huang1, B Byun, T Matsubara, M A Moskowitz.   

Abstract

1. The delayed effects of stimulating the trigeminal ganglion unilaterally in rats and guinea-pigs were assessed by measuring the leakage of radiolabelled albumin from blood into the dura mater at intervals for up to 120 min after a 5 min stimulation period (5 Hz, 0.6 mA, 5 ms). 2. [125I]-albumin (50 microCi kg-1) was injected i.v. as a tracer 0, 20, 50, 80 or 110 min after stimulation and the animals were killed 10 min later. Extravasation of plasma protein developed for up to 90 min poststimulation. 3. To examine the mechanism underlying delayed plasma protein extravasation, CP-93,129 (5-HT1B receptor agonist, 460 nmol.kg-1), sumatriptan (5-HT1B/D receptor agonist, 24 nmol kg-1), or neutral endopeptidase 24.11 (1 nmol kg-1) were administered 45 or 75 min after trigeminal stimulation and 5 min before radiolabelled albumin. The extravasation response was reduced at 45 min. CP-23,129 also blocked extravasation when injected 25 min after capsaicin administration (1 mumol kg-1). 4. If the tracer was injected 5 min prior to electrical trigeminal stimulation, endopeptidase 24.11 (1 nmol kg-1) given 10 min before stimulation blocked the leakage (as reported previously for CP-93,129 or sumatriptan). All three compounds blocked the leakage when administered 30 min (but not 60 min) poststimulation in this paradigm. 5. The data support the previously made contention that neuropeptide release from sensory fibres mediates the plasma extravasation response following trigeminal ganglion stimulation, and that release and plasma leakage continue many minutes beyond the stimulation period. Hence, drugs that inhibit neuropeptide release (CP-93,129, sumatriptan), or enhance breakdown of neuropeptide mediators(endopeptidase 24.11) block the delayed extravasation response. Extravasation developing later than 45 min poststimulation was not neurogenically mediated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383561      PMCID: PMC1907980          DOI: 10.1111/j.1476-5381.1993.tb12805.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Enkephalinase inhibitor potentiates mammalian tachykinin-induced contraction in ferret trachea.

Authors:  K Sekizawa; J Tamaoki; P D Graf; C B Basbaum; D B Borson; J A Nadel
Journal:  J Pharmacol Exp Ther       Date:  1987-12       Impact factor: 4.030

2.  Enkephalinase inhibitor potentiates substance P- and electrically induced contraction in ferret trachea.

Authors:  K Sekizawa; J Tamaoki; J A Nadel; D B Borson
Journal:  J Appl Physiol (1985)       Date:  1987-10

3.  Neutral endopeptidase modulates tachykinin-induced increase in vascular permeability in guinea pig skin.

Authors:  I Iwamoto; I F Ueki; D B Borson; J A Nadel
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

4.  5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis.

Authors:  T Sharp; S R Bramwell; D G Grahame-Smith
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

5.  Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches.

Authors:  K Saito; S Markowitz; M A Moskowitz
Journal:  Ann Neurol       Date:  1988-12       Impact factor: 10.422

6.  The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Authors:  M G Buzzi; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release.

Authors:  G Maura; M Raiteri
Journal:  Eur J Pharmacol       Date:  1986-10-07       Impact factor: 4.432

Review 8.  Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.

Authors:  M A Moskowitz
Journal:  Trends Pharmacol Sci       Date:  1992-08       Impact factor: 14.819

9.  Inhibition of neutral endopeptidase potentiates neurogenic inflammation in the rat trachea.

Authors:  E Umeno; J A Nadel; H T Huang; D M McDonald
Journal:  J Appl Physiol (1985)       Date:  1989-06

10.  Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain.

Authors:  S Markowitz; K Saito; M A Moskowitz
Journal:  J Neurosci       Date:  1987-12       Impact factor: 6.167

View more
  5 in total

1.  CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

Review 2.  Imaging the inflammatory phenotype in migraine.

Authors:  Rune Häckert Christensen; Cédric Gollion; Faisal Mohammad Amin; Michael A Moskowitz; Nouchine Hadjikhani; Messoud Ashina
Journal:  J Headache Pain       Date:  2022-06-01       Impact factor: 8.588

3.  The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.

Authors:  P Gupta; D Brown; P Butler; P Ellis; K L Grayson; G C Land; J E Macor; S F Robson; M J Wythes; N B Shepperson
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

4.  Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.

Authors:  W S Lee; S M Moussaoui; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

5.  Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.

Authors:  Paul Zarogoulidis; Maria Mavroudi; Konstantinos Porpodis; Kalliopi Domvri; Antonios Sakkas; Nikolaos Machairiotis; Aikaterini Stylianaki; Anastasios Tsiotsios; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  Onco Targets Ther       Date:  2012-09-27       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.